Skip to main content
Erschienen in: World Journal of Surgery 9/2018

06.03.2018 | Original Scientific Report

Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma

verfasst von: Tatsuaki Sumiyoshi, Yasuo Shima, Takehiro Okabayashi, Yuji Negoro, Yasuhiro Shimada, Jun Iwata, Manabu Matsumoto, Yasuhiro Hata, Yoshihiro Noda, Kenta Sui, Taijiro Sueda

Erschienen in: World Journal of Surgery | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Objective

Surgical resection is the only available treatment for achieving long-term survival in cholangiocarcinoma. The purpose of this study is to elucidate the utility of chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma.

Methods

Unresectable locally advanced cholangiocarcinoma was defined as those in which radical surgery could not be achieved even with aggressive surgical procedure. Fifteen candidates (7 intrahepatic cholangiocarcinomas and 8 hilar cholangiocarcinomas) underwent chemoradiotherapy. Fourteen of the 15 patients received oral S-1 chemotherapy. Radiotherapy was administered with 50 Gy for each patient. After chemoradiotherapy, the resectability of each cholangiocarcinoma was reexamined.

Results

Of the 15 patients with initially unresectable locally advanced cholangiocarcinoma, 11 (73.3%) were judged to have resectable cholangiocarcinoma after chemoradiotherapy, and received radical hepatectomy (R0 resection in 9 patients). Among the 11 patients who underwent surgical resection, 4 had recurrence-free survival and the median survival time (MST) was 37 months. The overall 1-, 2-, and 5-year survival rates were 80.8, 70.7 and 23.6%, respectively. Among the 4 patients who were unable to receive surgery, 3 died of the primary disease and the MST was 10 months. The overall 1- and 2-year survival rates were 37.5 and 0%, respectively. Patients who received radical surgery had significantly longer survival time than those who were unable to receive surgery (p = 0.027).

Conclusions

Chemoradiotherapy allowed patients with initially unresectable locally advanced cholangiocarcinomas to be reclassified as surgical candidates in a substantial proportion. Chemoradiotherapy might be one of the treatment options for similarly advanced cholangiocarcinomas.
Literatur
1.
Zurück zum Zitat Vauthey JN, Blumgart LH (1994) Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 14:109–114CrossRefPubMed Vauthey JN, Blumgart LH (1994) Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 14:109–114CrossRefPubMed
2.
Zurück zum Zitat Aljiffry M, Walsh MJ, Molinari M (2009) Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 15:4240–4262CrossRefPubMedPubMedCentral Aljiffry M, Walsh MJ, Molinari M (2009) Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 15:4240–4262CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Taylor-Robinson SD, Foster GR, Arora S et al (1997) Increase in primary liver cancer in the UK, 1979–94. Lancet 350:1142–1143CrossRefPubMed Taylor-Robinson SD, Foster GR, Arora S et al (1997) Increase in primary liver cancer in the UK, 1979–94. Lancet 350:1142–1143CrossRefPubMed
4.
Zurück zum Zitat Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353–1357CrossRefPubMed Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353–1357CrossRefPubMed
5.
Zurück zum Zitat Hong JC, Jones CM, Duffy JP et al (2011) Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 146:683–689CrossRefPubMed Hong JC, Jones CM, Duffy JP et al (2011) Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 146:683–689CrossRefPubMed
6.
Zurück zum Zitat Kato A, Shimizu H, Ohtsuka M et al (2013) Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol 20:318–324CrossRefPubMed Kato A, Shimizu H, Ohtsuka M et al (2013) Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol 20:318–324CrossRefPubMed
7.
8.
Zurück zum Zitat Nathan H, Aloia TA, Vauthey JN et al (2009) A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 16:14–22CrossRefPubMed Nathan H, Aloia TA, Vauthey JN et al (2009) A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 16:14–22CrossRefPubMed
9.
Zurück zum Zitat Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. ABC-02 Trial Investigators. N Engl J Med 362:1273–1281CrossRefPubMed Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. ABC-02 Trial Investigators. N Engl J Med 362:1273–1281CrossRefPubMed
10.
Zurück zum Zitat McMasters KM, Tuttle TM, Leach SD et al (1997) Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 174:605–609CrossRefPubMed McMasters KM, Tuttle TM, Leach SD et al (1997) Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 174:605–609CrossRefPubMed
11.
Zurück zum Zitat Nelson JW, Ghafoori AP, Willett CG et al (2009) Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 73:148–153CrossRefPubMed Nelson JW, Ghafoori AP, Willett CG et al (2009) Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 73:148–153CrossRefPubMed
12.
Zurück zum Zitat Kim YI, Park JW, Kim BH et al (2013) Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 8:292CrossRefPubMedPubMedCentral Kim YI, Park JW, Kim BH et al (2013) Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma. Radiat Oncol 8:292CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Shirasaka T, Shimamoto Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drug 7:548–557CrossRef Shirasaka T, Shimamoto Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drug 7:548–557CrossRef
14.
Zurück zum Zitat Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248–257CrossRefPubMed Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248–257CrossRefPubMed
15.
Zurück zum Zitat Ebata T, Nagino M, Kamiya J et al (2003) Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 238:720–727CrossRefPubMedPubMedCentral Ebata T, Nagino M, Kamiya J et al (2003) Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 238:720–727CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Igami T, Nishio H, Ebata T et al (2010) Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Sci 17:449–454CrossRefPubMed Igami T, Nishio H, Ebata T et al (2010) Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Sci 17:449–454CrossRefPubMed
17.
Zurück zum Zitat Nagino M, Ebata T, Yokoyama Y et al (2013) Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 258:129–140CrossRefPubMed Nagino M, Ebata T, Yokoyama Y et al (2013) Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 258:129–140CrossRefPubMed
18.
Zurück zum Zitat Rea DJ, Heimbach JK, Rosen CB et al (2005) Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242:451–461PubMedPubMedCentral Rea DJ, Heimbach JK, Rosen CB et al (2005) Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242:451–461PubMedPubMedCentral
19.
Zurück zum Zitat Darwish Murad S, Kim WR, Harnois DM et al (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143:88–98CrossRefPubMed Darwish Murad S, Kim WR, Harnois DM et al (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143:88–98CrossRefPubMed
20.
Zurück zum Zitat Rayar M, Levi Sandri GB, Houssel-Debry P et al (2016) Multimodal therapy including Yttrium-90 Radioembolization as a bridging therapy to liver transplantation for a huge and locally advanced intrahepatic cholangiocarcinoma. J Gastrointestin Liver Dis 25:401–454PubMed Rayar M, Levi Sandri GB, Houssel-Debry P et al (2016) Multimodal therapy including Yttrium-90 Radioembolization as a bridging therapy to liver transplantation for a huge and locally advanced intrahepatic cholangiocarcinoma. J Gastrointestin Liver Dis 25:401–454PubMed
21.
Zurück zum Zitat Rayar M, Sulpice L, Edeline J et al (2015) Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 22:3102–3108CrossRefPubMed Rayar M, Sulpice L, Edeline J et al (2015) Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 22:3102–3108CrossRefPubMed
Metadaten
Titel
Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma
verfasst von
Tatsuaki Sumiyoshi
Yasuo Shima
Takehiro Okabayashi
Yuji Negoro
Yasuhiro Shimada
Jun Iwata
Manabu Matsumoto
Yasuhiro Hata
Yoshihiro Noda
Kenta Sui
Taijiro Sueda
Publikationsdatum
06.03.2018
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 9/2018
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-018-4558-1

Weitere Artikel der Ausgabe 9/2018

World Journal of Surgery 9/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.